Novasecta’s Managing Partner, John Rountree, was asked by Bloomberg to comment on the recent Sanofi and Celgene deals. Reflecting on our experience with listed pharmaceutical companies, John commented “Pharmaceutical companies are increasingly turning to specialty areas like hemophilia because of the opportunities for higher prices.” and that “It’s all about finding niches. Pricing for cell and gene therapies remains more uncertain than some other new treatments”. For more on Novasecta’s perspective on the high prices paid to execute M&A click here. To view the full Bloomberg article, click here.
Novasecta’s Managing Partner, John Rountree, was asked by Bloomberg to comment on the threat AstraZeneca poses to GSK. John highlighted the approach of AstraZeneca’s Chief Executive Pascal Soriot commenting “Soriot took a very bold approach, saying it’s got to be about innovation and the pipeline, which means we’re going to have to take some risks. That also puts you on a more volatile path.” This is not the first time John’s opinion has been sort on the threat GSK feels from AstraZeneca, previous comments in the Daily Telegraph emphasise their different approaches to R&D. To view the full Bloomberg article, click here.